The Impact of the SLCO1B1 Gene Polymorphism on the Lipid-Lowering Effect of Pitavastatin
H. Yuan,X. Lu,Z. J. Huang,B. Tang,G. P. Yang
DOI: https://doi.org/10.1016/j.ijcard.2009.09.350
IF: 4.039
2009-01-01
International Journal of Cardiology
Abstract:Objective To discuss the impact of the SLCO1B1 521T>C gene polymorphism on the lipid-lowering effect of pitavastatin in primary hypercholesterolemia patients. Methods 150 primary hypercholesterolemia patients had been investigated in Changsha. Excluding possible influencing factors such as sex, age, weight and complications, the patients were divided into two groups stochastically, administered pitavastatin 2 mg/d or lovastatin 20 mg/d orally before sleeping, and followed-up in 8 weeks. The SLCO1B1 521T>C spot gene polymorphism was tested through allele specificity PCR (ARMS-PCR) and polymerase chain reaction-restrictive piece length polymorphism (PCR-RFLP). Total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C) were tested before and after the intervention, meanwhile, the vital signs, urine routine, liver function and renal function were observed. Results 1) There is no significant difference (P>0.05) in the general situation in the two groups originally. After 8 weeks, the total effective rate of pitavastatin is 83.3%, the changes of blood lipids and total effective rate have no significant difference statistically significant (P>0.05); 2) the frequency of the SLCO1B1 521T>C allelic mutation is 11.1% and 71.1%. The 521T homozygous wild-type accounts for 79.3% of the total, and for 521TC and 521CC, respectively, the numbers are 19.3% and 1.4%. Distribution of alleles and genotypes is consistent with the law of Hardy–Weinberg balance; 3) for plasma TC, the rate of change is (−24.3±4.2)% in the TT group while in the TC/CC group the data is (11.1±3.4)%, the effect of pitavastatin on TC-lowering in the TT group is significantly superior to that in the TC/CC group (P<0.05), for TG, LDL-C and HDL-C, there is no significant difference (P>0.05). Conclusions In primary hypercholesterolemia patients, the total effective rate of pitavastatin 2 mg/d orally is 83.3%, and the SLCO1B1 521T>C gene mutation may take effect in lowering TC from pitavastatin. Objective To discuss the impact of the SLCO1B1 521T>C gene polymorphism on the lipid-lowering effect of pitavastatin in primary hypercholesterolemia patients. Methods 150 primary hypercholesterolemia patients had been investigated in Changsha. Excluding possible influencing factors such as sex, age, weight and complications, the patients were divided into two groups stochastically, administered pitavastatin 2 mg/d or lovastatin 20 mg/d orally before sleeping, and followed-up in 8 weeks. The SLCO1B1 521T>C spot gene polymorphism was tested through allele specificity PCR (ARMS-PCR) and polymerase chain reaction-restrictive piece length polymorphism (PCR-RFLP). Total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C) were tested before and after the intervention, meanwhile, the vital signs, urine routine, liver function and renal function were observed. Results 1) There is no significant difference (P>0.05) in the general situation in the two groups originally. After 8 weeks, the total effective rate of pitavastatin is 83.3%, the changes of blood lipids and total effective rate have no significant difference statistically significant (P>0.05); 2) the frequency of the SLCO1B1 521T>C allelic mutation is 11.1% and 71.1%. The 521T homozygous wild-type accounts for 79.3% of the total, and for 521TC and 521CC, respectively, the numbers are 19.3% and 1.4%. Distribution of alleles and genotypes is consistent with the law of Hardy–Weinberg balance; 3) for plasma TC, the rate of change is (−24.3±4.2)% in the TT group while in the TC/CC group the data is (11.1±3.4)%, the effect of pitavastatin on TC-lowering in the TT group is significantly superior to that in the TC/CC group (P<0.05), for TG, LDL-C and HDL-C, there is no significant difference (P>0.05). Conclusions In primary hypercholesterolemia patients, the total effective rate of pitavastatin 2 mg/d orally is 83.3%, and the SLCO1B1 521T>C gene mutation may take effect in lowering TC from pitavastatin.